Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Inclusion Criteria

• •Pathology confirmation of HL with City of Hope (COH) pathology review
• •Hodgkin lymphoma that is:
• •* PIF (primary induction failure): did not enter complete remission with first line of therapy; Note: a patient with PIF who responds to salvage therapy with a PR or CR is also eligible (and would be considered PIF-sensitive)
• •* Early 1st relapse: initial CR of \> 3 months and \< 12 months after 1st line chemotherapy
• •* 1st relapsed HL in a patient who is not in CR after 2 cycles of salvage therapy
• •* In 2nd or subsequent relapse (RL) whether in CR or not after salvage therapy
• •Relapse/persistent disease evidenced by a computed tomography and fluorodeoxyglucose (FDG)-positron emission tomography (PET), or bone marrow biopsy
• •Cardiac ejection fraction of \>= 50% by echocardiogram or multi gated acquisition scan (MUGA)
• •Forced expiratory volume in one second (FEV1) \> 65% of predicted measured, or diffusion capacity of the lung for carbon monoxide (DLCO) \>= 50% of predicted measured
• •Bilirubin =\< 1.5 x normal
• •Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =\< 2 x normal except in cases where abnormal liver function tests (LFTS) are due to involvement with HL
• •Serum creatinine of =\< 1.5 mg/dL, and a measured creatinine clearance of \>= 60 mL/min
• •Karnofsky status \>= 70%
• •Life expectancy \>= 6 months
• •Females must not be pregnant or breast feeding, and must use accepted birth control methods; males must use accepted birth control methods
• •Capability of providing informed consent
• •Patients will be enrolled after receiving at least two cycles of salvage cytoreductive chemotherapy and collection of at least 3.0 x 10\^6 CD34 cells/kg of autologous hematopoietic progenitor cells (HPC-A) by apheresis; a minimum of 2 collection procedures is required, unless collection on day #1 \> 5.0 x 10\^6 CD34 cells/kg; a maximum of 10 collections is allowed; bone marrow harvest to supplement apheresis is not allowed
• •Co-enrollment on Institutional Review Board (IRB) #98117, entitled Molecular Pathogenesis of Therapy-Related Leukemia
• •All pre-study and follow-up imaging studies preferably performed at City of Hope
• •Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to =\< grade 2 (Common Terminology Criteria for Adverse Events version 4 \[CTCAE v4\])
• •Body mass index (BMI) \> 30% will be considered on a case-by-case basis by the radiation oncology principal investigator (PI)
• •While on this study, patients may not be treated with any other investigational agent for any purpose until relapse or progression